Sunday, March 4, 2018

Another Phase III Win For Neurocrine Biosciences

Good news continues to stack up for Neurocrine Biosciences (NBIX), with the company's partner AbbVie (ABBV) announcing on Wednesday that its first of two Phase III studies of elagolix in uterine fibroids met all of its efficacy endpoints. This continues a pretty good run of success with Neurocrine's late-stage pipeline and brings another potential multi-billion-dollar drug that much closer to approval and commercialization.

While there are still more steps to go through with elagolix in uterine fibroids (namely, full results from both studies, including safety data), the similarities between the Phase III and Phase II results thus far would suggest that there's not much reason for worry (then again "surprises" are by their nature not expected…). Approval of elagolix in 2019 or 2020 would bring another important revenue generator to market for Neurocrine and this incremental step does modestly boost my fair value.

Continue here:
Another Phase III Win For Neurocrine Biosciences

No comments: